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Abstract
Background: Interferon and ribavirin therapy for chronic hepatitis C virus (HCV) infection yields sustained virological
response (SVR) rates of 50–80%. Several factors such as non-1 genotype, beneficial IL28B genetic variants, low baseline IP-10,
and the functionality of HCV-specific T cells predict SVR. With the pending introduction of new therapies for HCV entailing
very rapid clearance of plasma HCV RNA, the importance of baseline biomarkers likely will increase in order to tailor therapy.
CD26 (DPPIV) truncates the chemokine IP-10 into a shorter antagonistic form, and this truncation of IP-10 has been
suggested to influence treatment outcome in patients with chronic HCV infection patients. In addition, previous reports
have shown CD26 to be a co-stimulator for T cells. The aim of the present study was to assess the utility of CD26 as a
biomarker for treatment outcome in chronic hepatitis C and to define its association with HCV-specific T cells.
Methods: Baseline plasma from 153 genotype 1 and 58 genotype 2/3 infected patients enrolled in an international
multicenter phase III trial (DITTO-HCV) and 36 genotype 1 infected patients participating in a Swedish trial (TTG1) were
evaluated regarding baseline soluble CD26 (sCD26) and the functionality of HCV-specific CD8+ T cells.
Results: Genotype 1 infected patients achieving SVR in the DITTO (P = 0.002) and the TTG1 (P= 0.02) studies had lower
pretreatment sCD26 concentrations compared with non-SVR patients. Sixty-five percent of patients with sCD26
concentrations below 600 ng/mL achieved SVR compared with 39% of the patients with sCD26 exceeding 600 ng/mL
(P= 0.01). Patients with sCD26 concentrations below 600 ng/mL had significantly higher frequencies of HCV-specific CD8+ T
cells (P = 0.02).
Conclusions: Low baseline systemic concentrations of sCD26 predict favorable treatment outcome in chronic HCV infection
and may be associated with higher blood counts of HCV-specific CD8+ T cells.
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Introduction
Until recently, the standard-of-care therapy for patients
chronically infected with hepatitis C virus (HCV) has been a
combination of pegylated interferon-a (pegIFN-a) and ribavirin.
This treatment results in sustained virological response (SVR) rates
of 50–80% [1]. In addition to HCV non-1 genotypes, factors such
as lower baseline HCV RNA levels, lower body mass index (BMI),
younger age, female gender, lower alanine transaminase (ALT),
less advanced liver fibrosis, and beneficial IL28B single nucleotide
polymorphisms (SNPs) are associated with a favorable treatment
response [2–6]. Additionally, the newly approved HCV protease
inhibitors have entailed significantly improved outcome for HCV
genotype 1 infected patients [7,8]. With the pending introduction
of newer Direct-Acting Antiviral (DAA) agents, e.g. nucleotide
NS5B inhibitors, which yield very rapid initial clearance of plasma
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HCV RNA but yet sizeable relapse rates [9], especially in difficult-
to-cure genotype 1a infected patients, the importance of baseline
biomarkers likely will increase in order to tailor choice of therapy
and treatment duration.
High systemic and intra-hepatic levels of the IFN-c-inducible
protein 10 kDa (IP-10 or CXCL10) predict treatment failure
following pegIFN-a-based therapy in chronic HCV infection [10–
15]. In addition, reports have shown both IP-10 and the IL28B
SNP variations to be associated with the antiviral response to
pegIFN-a/ribavirin therapy [10,13,16]. IP-10 attracts T cells, NK
cells, and monocytes to the site of infection via the CXC
chemokine receptor 3 (CXCR3) [17]. IP-10 is degraded into an
antagonistic form by the dipeptidyl peptidase enzymatic activity of
CD26 (also known as DPPIV), a serine protease that cleaves a
dipeptide from the N-terminus of polypeptides with either a
proline or alanine at the penultimate position [18,19]. A recent
study by Casrouge et al. reported that patients failing therapy have
higher baseline plasma DPPIV activity [20]. The authors
suggested that a subsequent systemic accumulation of the
truncated antagonistic form of IP-10 impairs migration of
CXCR3+ cells to the infected liver. CD26 is present both as a
membrane-bound and as a soluble (sCD26) form, and the DPPIV
activity of the membrane-bound form has been suggested to be
important for T cell activation [21] possibly by associating with
CD45 [22]. Also, sCD26 has been shown to enhance CD86
expression on antigen-presenting cells [23].
Dysfunctional exhausted HCV-specific T cells have been
associated both with the establishment of HCV chronicity
[24,25] and with treatment failure following pegIFN-a-based
therapy [26]. In line with these findings, functional HCV-specific
T cell responses were observed in patients spontaneously resolving
acute HCV infection [27] and in chronically infected patients
achieving SVR following treatment [28]. The aim of the present
study was to evaluate the impact of sCD26 on the outcome of
HCV therapy and its association with the functionality of HCV-
specific T cells.
Methods
Ethical Aspects
The treatment studies conformed to the guidelines of the 1975
Declaration of Helsinki and were approved by ethical committees
at each center (Medicinska fakultetens forskningsetikkommitte´,
Go¨teborgs Universitet, Gothenburg, Sweden, CPP-Ile-de-France
IX, CHU Henri Mondor, Creteil, France, Comitato Etico
Indipendente (IRB/IEC) dell’Azienda Ospedaliera di Parma,
Parma, Italy, Comite d’Ethique du department de Medicine,
Hopitaux Universitaires de Gene`ve, Geneva, Switzerland, the
Helsinki committee of the Kaplan Medical Center, Rehovot,
Israel, the Ethics Committee of Hospital General Vall d’Hebron,
Barcelona, Spain, the Ethics Committee of Aristotle University of
Thessaloniki, Thessaloniki, Greece, the Ethics Committee of
Klinikum der Johann Wolfgang Goethe-Universitat, Frankfurt,
Germany, and the Ethics Committee of University Hospital
Rotterdam Dijkzigt, Rotterdam, Netherlands). Written informed
consent was obtained from each participating patient.
Patients
Between February 2001 and November 2003, 270 patients were
recruited in a phase III, open-label, randomized, multicenter trial
conducted by the DITTO-HCV study group at nine centers in
France, Germany, Greece, Israel, Italy, Netherlands, Spain,
Table 1. Baseline and on-treatment characteristics of the genotype 1 patients in the complete DITTO study, the genotype 1
patients available for the present study, and the genotype 1 patients available for the T cell study.
Complete genotype 1
DITTO cohort (n = 173) cP
Genotype 1 patients
included (n = 153) dP
Genotype 1 T cell
study patients (n = 24)
Log10 HCV RNA (IU/mL) decline
1st day on treatment
0.67 (21.05–3.07) 1.0a 0.67 (21.05–3.07) 0.5a 0.62 (0.24–2.46)
Log10 HCV RNA (IU/mL) decline
day 8 to 29 on treatment
1.48 (22.94–5.81) 0.8a 1.39 (22.94–5.81) 0.1a 0.89 (0.36–4.52)
RVR 38 (22%) 0.8b 35 (23%) 0.8b 5 (21%)
SVR 93 (54%) 0.9b 81 (53%) 0.8b 12 (50%)
Female 52 (30%) 0.9b 47 (31%) 0.5b 9 (38%)
BMI (kg/m2) 24.6 (18.8–39.9) 1.0a 24.4 (18.8–39.8) 0.2a 26.0 (11.5–20.3)
Age (years) 43.0 (18.0–64.0) 1.0a 42.0 (18.0–64.0) 0.2a 44.0 (30.0–64.0)
IP-10 (pg/mL) 240 (29.0–2244) 1.0a 240 (29.0–2200) 0.6a 286 (49–706)
IP-10 (,150/150–600/.600 pg/mL) 47/102/24 1.0b 42/89/22 0.5b 5/17/2
sCD26 (ng/mL) n.a. n.a. 588 (66–1696) 0.3a 525 (187–1013)
DPPIV (AU) n.a. n.a. 31.6 (15.6–113.1) 0.2a 37.7 (18.0–113.0)
HCV RNA (IU/mL) 6.27 (2.92–7.38) 0.7a 6.19 (2.92–7.22) 0.7a 6.35 (4.16–7.21)
rs12979860 (CC/CT/TT) 46/98/29 1.0b 40/88/25 0.3b 6/17/1
rs8099917 (TT/TG/GG) 99/67/7 0.9b 85/61/7 0.9b 12/11/1
rs12980275 (AA/AG/GG) 54/90/29 1.0b 47/81/25 0.2b 7/16/1
ALT (IU/L) 50.5 (18.0–335.3) 0.9a 56.0 (18.0–335.3) 0.7a 76.9 (25.0–224.0)
Fibrosis Stage (Ishak 0/1/2/3/4/5/6) 11/46/40/20/10/12/10 1.0b 10/40/35/15/8/12/10 0.8b 2/4/6/3/1/1/0
Median (range) or individuals (percent). Statistics using aMann-Whitney U test and bx2 test.
cP-value for all genotype 1 patients in the complete DITTO study compared with the patients available for sCD26 analysis.
dP-value for all genotype 1 patients available for analysis of sCD26 compared with HLA-A2 or HLA-A3 patients available for the tetramer study. n.a. = not applicable.
doi:10.1371/journal.pone.0056991.t001
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Sweden, and Switzerland, as previously reported [29]. All patients
were adults, had compensated liver disease, were treatment-naı¨ve
for hepatitis C, and fulfilled the following inclusion criteria: a
positive test for anti-HCV antibody, baseline HCV RNA above
1000 IU/mL, and two serum alanine aminotransferase values
above the upper limit of normal within 6 months of treatment
initiation. The present study included the 211 of the initial 250
genotype 1–3 patients in the DITTO study where previously
unthawed plasma samples were available. Baseline plasma samples
for 153 genotype 1 (Table 1) and 58 genotype 2/3 (Table 2)
patients were analyzed for sCD26 concentrations, and all of them
had previously been analyzed for both IL28B genetic variants
[13,16] and baseline plasma IP-10 [14,15]. Twenty-eight human
leukocyte antigen (HLA)-A2 and HLA-A3 positive (Table 1 and 2)
patients chosen based on the availability of sufficient numbers of
viable peripheral blood mononuclear cells (PBMCs) were studied
for HCV-specific HLA class I responses before treatment
initiation, as previously described [28]. The plasma samples were
stored in aliquots at 280uC and the PBMCs were stored in liquid
nitrogen until assayed.
The second study (the TTG1 trial) was conducted between
2008 and 2010 in 106 Swedish patients chronically infected
with genotype 1. For the present study, previously unthawed
samples from 36 patients treated at the Sahlgrenska University
Hospital, Gothenburg, Sweden were retrieved for analysis. The
plasma samples were stored in aliquots at 280uC until assayed.
Treatment
All patients in the DITTO-HCV trial were initially treated for
six weeks with 180 mg pegIFN-a2a administrated by subcutaneous
injections once weekly (Pegasys, F. Hoffmann-LaRoche, Basel,
Switzerland) and ribavirin orally twice daily (Copegus, F.
Hoffmann-LaRoche) at a total daily dose of 1,000 mg for patients
weighing less than 75 kg and 1,200 mg daily for above 75 kg.
After six weeks of therapy, 50% of the patients were randomized
based on their viral kinetic classification to receive individualized
therapy or to continue on standard combination therapy for a total
of 48 weeks. There were, however, no major differences in
treatment outcome for patients receiving individualized or
standard therapy [29]. Patients were classified as having SVR if
HCV RNA was undetectable in plasma 24 weeks after the
completion of therapy and classified as having a rapid virological
response (RVR) if HCV RNA was undetectable in plasma week 4
after treatment initiation.
For the TTG1 trial, patients were randomized to receive 180 mg
pegIFN-a2a subcutaneous injections once weekly and ribavirin
orally twice daily at a total daily dose of 1,000 mg for patients
weighing less than 75 kg and 1,200 mg daily for above 75 kg either
for the standard-of-care (SOC) response-guided duration or individ-
ually tailoredtreatmentduration.ThetreatmentdurationintheSOC
group was 24, 48, or 72 weeks depending on whether HCV RNA was
undetectable after 4, 12, or 24 weeks of treatment, with patients
discontinuing if HCV RNA had not declined by at least 2 log10 IU/
mL after 12 weeks. In the tailored group, there was a flexible
treatment duration depending on rate of HCV RNA decline.
Table 2. Baseline and on-treatment characteristics of the genotype 2/3 patients in the complete DITTO study, the genotype 2/3
patients available for the present study, and the genotype 2/3 patients available for the T cell study.
Complete genotype 2/3
DITTO cohort (n = 77) cP
Genotype 2/3 patients
included (n = 58) dP
Genotype 2/3 T cell study
patients (n = 4)
Log10 HCV RNA (IU/mL) decline
1st day on treatment
1.83 (20.66–4.18) 0.8a 1.82 (0.12–3.14) 0.3a 2.19 (1.02–2.50)
Log10 HCV RNA (IU/mL) decline
day 8 to 29 on treatment
2.51 (0.00–4.65) 0.9a 2.51 (0.00–4.65) 0.1a 1.26 (0.00–3.24)
RVR 62 (81%) 0.7b 45 (78%) 0.6b 4 (100%)
SVR 68 (88%) 0.2b 55 (95%) 1.0b 4 (100%)
Genotype (2/3) 24/53 0.5b 21/37 0.6b 2/2
Female 29 (38%) 0.7b 24 (41%) 1.0b 2 (50%)
BMI (kg/m2) 24.6 (18.7–32.4) 0.5a 25.3 (19.3–32.4) 0.9a 24.9 (22.8–29.4)
Age (years) 42.0 (20.0–66.0) 0.7a 43.0 (20.0–66.0) 1.0a 42.5 (36.0–49.0)
IP-10 (pg/mL) 188 (43–2200) 0.9a 199 (43–1843) 0.04a 97 (64–157)
IP-10 (,150/150–600/.600 pg/mL) 28/42/7 1.0b 21/32/5 0.3b 3/1/0
sCD26 (ng/mL) n.a. n.a. 505 (75–1134) 0.8b 493 (389–610)
DPPIV (AU) n.a. n.a. 32.3 (9.0–60.0) 0.4b 28.5 (11.0–54.0)
HCV RNA (IU/mL) 6.43 (3.14–7.43) 0.7a 6.48 (3.14–7.43) 0.9a 6.35 (4.16–7.21)
rs12979860 (CC/CT/TT) 50/23/4 0.9b 36/18/4 0.2b 1/3/0
rs8099917 (TT/TG/GG) 57/19/1 0.9b 41/16/1 0.6b 2/2/0
rs12980275 (AA/AG/GG) 50/23/4 0.9b 37/17/4 0.2b 1/3/0
ALT (IU/L) 96.0 (25.0–702.0) 0.8a 95.4 (25.0–702.0) 0.6a 79.5 (41.3–192.0)
Fibrosis Stage (Ishak 0/1/2/3/4/5/6) 0/15/23/10/7/7/4 1.0b 0/12/16/9/5/6/2 0.2b 0/0/4/0/0/0/0
Median (range) or individuals (percent). Statistics using aMann-Whitney U test and bx2 test.
cP-value for all genotype 2/3 patients in the study compared with the patients available for sCD26 analysis.
dP-value for all genotype 2/3 patients available for analysis of sCD26 compared with HLA-A2 or HLA-A3 patients available for the tetramer study. n.a. = not applicable.
doi:10.1371/journal.pone.0056991.t002
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HCV Genotyping
Genotyping of HCV was for the DITTO-HCV trial performed
using INNO-LiPA HCV II (Innogenetics N.V., Ghent, Belgium)
and for the TTG1 trial using Taqman real-time PCR [30].
HCV RNA Quantification
HCV RNA was quantified in the DITTO study using Cobas
Amplicor (Roche Diagnostics, Branchburg, NJ) on days 0, 1, 4, 7,
8, 15, 22, 29, and weeks 6, 7, 8, 10, 12, 18, 24, 30, 36, 42, 48, 54,
as well as 24 weeks after the completion of the treatment. Samples
in the TTG1 study were obtained at baseline and after 1, 2, 3, 4, 7,
8, 12, 16, 20, and 24 weeks of treatment.
Characterization of Single Nucleotide Polymorphisms
The IL28B-related SNPs rs12979860, rs12980275 and
rs8099917 were determined for the DITTO-HCV trial with
TaqMan SNP genotyping assays (Applied Biosystems Inc., Foster
City, CA) as previously described [13], and the IL28B-related
SNPs rs12979860 and rs8099917 were for the TTG1 trial
Figure 1. CD26 in genotype 1 patients from the DITTO-HCV and TTG studies grouped depending on treatment outcome.
Pretreatment plasma sCD26 concentrations (ng/mL) (A) and DPPIV activity (AU) (B) in patients from the DITTO-HCV study, and pretreatment plasma
sCD26 concentrations (ng/mL) (C) in the TTG1 study grouped depending of treatment outcome. Box plots display the 10th, 25th, 50th, 75th, and 90th
percentiles. The dashed line indicates the 600 ng/mL sCD26 cut-off concentration. Statistics analysis using two-tailed Mann-Whitney U-test.
doi:10.1371/journal.pone.0056991.g001
Figure 2. ROC analysis and assessment of the sCD26 concentration cut-off value. (A) ROC curve analysis of the indicated baseline factors
with the AUC value. A diagonal reference line is shown using a dashed line. (B) TG-ROC analysis for determining the cut-off value for the sCD26
concentration show the sensitivity and the specificity from the ROC curve. The dashed line indicates where the sensitivity and specificity intersects.
doi:10.1371/journal.pone.0056991.g002
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determined by allelic discrimination using Taqman MGB (minor
groove binding) probes [31].
Analysis of sCD26 Concentration
Concentrations (ng/mL) of soluble CD26/DPPIV, human
sCD26 ELISA (BMS235CE, eBioscience, San Diego, CA, USA)
were quantified according to the manufacturer’s protocol with the
plasma samples diluted 1:5 in sample diluent [32].
Analysis of DPPIV Activity
The DPP enzymatic activity of sCD26 was measured using the
DPPIV-GloTM Protease Assay (Promega, Madison, WI, USA),
which is based on the cleavage of a pre-obtained substrate (Gly-
Pro-aminoluciferin) by DPPIV [20], followed by light production
measured as luciferase activity. The luminescent signal recorded
for 0.1 seconds, defined as relative light units (RLU), is
proportional to the total amount of DPPIV activity in each
sample. The assay used 50 mL 0.2% diluted plasma sample and
50 mL freshly prepared CD26/DPPIV-GloTM reagent followed by
an incubation time of 30 minutes at room temperature in
accordance with the manufacturer’s protocol, with 50 mL PBS
used as negative control. The DPPIV activity is presented as an
arbitrary unit (AU) giving the RLU sample/RLU PBS quotient.
Analysis of IP-10 Concentration
Quantification of IP-10 in the baseline plasma samples was
performed using a solid-phase IP-10 ELISA (R&D SYSTEMS,
Minneapolis, MN, USA) according to manufacturer’s protocol
[33] but with plasma samples diluted 1:4 using assay diluent.
Fibrosis Classification
The pretreatment liver biopsies were previously analyzed in a
blinded fashion according to the Ishak protocol [14].
HCV Peptides and Peptide-HLA Class I Tetramers
Synthetic peptides corresponding to different HLA-A2 and
HLA-A3 restricted HCV genotype 1a sequences [34] from
different nonstructural (NS) HCV proteins were purchased from
Chiron Mimotopes: HLA-A2 NS3 CINGVCWTV1073–1081,
HLA-A2 NS3 KLVALGINAV1406–1415, HLA-A3 NS3
LIFCHSKKK1391–1399, HLA-A2 NS4 LLFNILGGWV1807–1816,
HLA-A3 NS4 GVAGALVAFK1858–1867, HLA-A3 NS5 RVCEK-
MALY2588–2596, and HLA-A2 NS5 ALYDVVTKL2594–2602.
Individual tetrameric peptide-HLA class I complexes containing
the above peptides were purchased from Proimmune LTD
(Oxford, UK).
Expansion, and Tetramer or Intracellular IFN-c Staining in
Short-term CD8+ T cell Lines
Peptide specific polyclonal CD8+ T cell lines were generated
from frozen PBMCs previously isolated from fresh heparinized
blood from 24 genotype 1 and four genotype 2 or 3 patients by
Ficoll-Hypaque density gradient centrifugation and resuspended
to 36105/well in RPMI-1640 supplemented with 25 mmol/L
HEPES, 2 mmol/L L-glutamine, 50 mg/mL gentamycin, and
10% human serum (complete medium) containing interleukin (IL)-
7 (5 ng/mL; Endogen, Woburn, MA) and IL-12 (100 pg/mL;
R&D Systems, Abingdon, UK) and stimulated with 1 mmol/L
final concentration HLA-A2 or HLA-A3 restricted HCV peptides.
Recombinant IL-2 (50 U/mL; EuroCetus, Amsterdam, The
Netherlands) was added on day 3 of culture. After 10 days of
culture at +37uC with 5% CO2, the CD8+ T cell lines were
washed, stained for tetramer-positive cells, or resuspended to
26106/mL in complete medium and stimulated with the same
peptides at 1 mg/mL at +37uC in 5% CO2. As controls, medium
or an irrelevant peptide were added. Brefeldin-A (10 mg/ml;
Sigma Chemical Co, St. Louis, MO) was added after one hour.
After five hours of stimulation, the cells were stained with
Table 3. On-treatment responses of the DITTO-HCV genotype 1 patients grouped below or above the sCD26 600 ng/mL cut-off
concentration prior to start of therapy.
,600 ng/mL (n = 81) .600 ng/mL (n = 72) P
Log10 HCV RNA (IU/mL) decline 1
st day on
treatment
0.91 (20.72–3.07) 0.61 (21.05–2.3) 0.005a
Log10 HCV RNA (IU/mL) decline day 8 to 29 on
treatment
1.60 (20.40–4.89) 1.18 (22.94–5.81) 0.06a
RVR 23 (28%) 12 (17%) 0.09b
SVR 53 (65%) 28 (39%) 0.01b
Median (range) or individuals (percent). Statistics using aMann-Whitney U test and bx2 test.
doi:10.1371/journal.pone.0056991.t003
Figure 3. Baseline sCD26 concentrations in genotype 1, 2 and 3
patients in the DITTO-HCV study. Pretreatment plasma sCD26
concentrations (ng/mL) in patients grouped depending on genotype
(Gt). Box plots display the 10th, 25th, 50th, 75th, and 90th percentiles. The
dashed line indicates the 600 ng/mL sCD26 cut-off concentration.
Statistics analysis for genotype 1 vs. genotype 2 and 3 using two-tailed
Mann-Whitney U-test.
doi:10.1371/journal.pone.0056991.g003
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allophycocyanin-labeled anti-CD8 and peridinin chlorophyll
protein-labeled anti-CD3 MoAb, fixed and permeabilized with
Cytofix/Cytoperm (BD Bioscience, San Jose, CA) followed by
phycoerytrin-labled anti-human IFN-c (Sigma) labeling. Intracel-
lular IFN-c expressions in CD8+CD3+ cells were analyzed on a
FACS-Calibur flow cytometer using CELLQuest software (BD).
Background IFN-c-positive CD8+ cells values in cells stimulated
with controls (range 0%–0.4%) were subtracted from the values of
the restimulated cells. CD8+ T cells without detectable IFN-c
expression were given a value of 0.009% to be able to be visualized
using a log10 scale.
Statistical Analyses
Mann Whitney-U test, Spearman correlation (rs), Kruskal-
Wallis test, x2 test, receiver operating characteristic (ROC)
calculating the area under the curve (AUC), and stepwise binary
logistic regression analyses were used. The sCD26 concentration
cut-off value was determined from the intersection of the sensitivity
and specificity obtained in the ROC analysis using a two graph-
ROC (TG-ROC) curve [35]. All statistical analyses were
performed using Prism (Version 5.0c, GraphPad Software, La
Jolla, CA) or SPSS (Version 20.0.0, IBM Corp, Armonk, NY,
USA) software. All reported P-values are two-sided.
Results
sCD26 and Treatment Outcome in Genotype 1–3 Patients
from Two Independent Studies
Eighty-four percent of the genotype 1–3 patients included in the
DITTO study were available for sCD26 analysis. Neither the
included genotype 1 (Table 1) nor genotype 2/3 (Table 2) patients
differed significantly regarding the evaluated parameters com-
pared with the full DITTO study cohort. The included genotype 1
patients from the DITTO study who responded to therapy
displayed significantly lower baseline sCD26 concentration
(P= 0.002; Figure 1A) and significantly lower DPPIV activity
(P= 0.02; Figure 1B) compared with patients failing treatment.
There was an overall weak, albeit highly significant, correlation
between the sCD26 concentration and the DPPIV activity
(rs = 0.35, P= 0.0001, n = 150).
A ROC analysis was performed to evaluate the baseline sCD26
concentration with regards to previously established predictors of
SVR. The baseline levels of HCV RNA (0.666) and IP-10 (0.662)
showed the highest AUC values followed by the baseline sCD26
concentration (0.647) and the DPPIV activity (0.645; Figure 2A).
The TG-ROC analysis determined the baseline sCD26 concen-
tration cut-off value for the genotype 1 patients in the DITTO
study to 600 ng/mL sCD26 by choosing the sCD26 concentration
where the sensitivity intersected with the specificity (Figure 2B)
Table 4. Baseline characteristics of the DITTO-HCV genotype 1 patients grouped below or above the sCD26 600 ng/mL cut-off
concentration prior to start of therapy.
,600 ng/mL (n = 81) .600 ng/mL (n = 72) P
Female 31 (38%) 16 (22%) 0.03a
BMI (kg/m2) 24.0 (18.8–35.1) 25.1 (19.1–39.8) 0.02b
Age (years) 40.0 (22.0–64.0) 43.0 (18.0–64.0) 0.6b
IP-10 (pg/mL) 208 (29.0–2200) 280 (53.0–2200) 0.04b
IP-10 (,150/150–600/.600 pg/mL) 26/45/10 16/44/12 0.4a
DPPIV activity (AU) 28.7 (15.6–66.9) 36.7 (16.7–113) 0.001b
HCV RNA (IU/mL) 6.13 (2.92–7.17) 6.38 (4.36–7.22) 0.02b
rs12979860 (CC/CT/TT) 23/46/12 17/42/13 0.7a
rs8099917 (TT/TG/GG) 45/33/3 40/28/4 0.9a
rs12980275 (AA/AG/GG) 28/40/13 19/41/12 0.5a
ALT (IU/L) 73.0 (18.0–287.4) 77.0 (18.0–335.3) 0.03b
Fibrosis Stage (Ishak 0/1/2/3/4/5/6) 6/24/19/7/5/2/4 4/16/16/8/3/10/6 0.2a
Median (range) or individuals (percent). Statistics using ax2 test and bMann-Whitney U test.
doi:10.1371/journal.pone.0056991.t004
Table 5. Odds ratio (OR) and stepwise binary logistic regression analysis identifying pretreatment factors independently predictive
of SVR in DITTO-HCV genotype 1 patients.
Parameter OR Binary logistic regression analysis (P)
HCV RNA (log10 IU/mL) 0.300 (0.150–0.599) 0.001
Gender (Male) 0.265 (0.108–0.650) 0.004
BMI (kg/m2) 0.867 (0.774–0.970) 0.01
sCD26 (ng/mL) 0.999 (0.997–1.000) 0.049
rs12980275 (AA/AG/GG) 0.497 (0.270–0.915) 0.03
OR with 95% confidence intervals for the factors analyzed, with values going from low to high or as indicated in the parenthesis.
doi:10.1371/journal.pone.0056991.t005
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[36]. The patients with sCD26 concentrations,600 ng/mL had a
significantly greater decline in HCV RNA day 0 to 1 (P= 0.005) as
well as a significant higher likelihood of achieving SVR (P= 0.01)
(Table 3). Patients with lower sCD26 concentrations also showed
significantly lower concentrations of IP-10 (P= 0.04), as well as
lower levels of HCV RNA (P= 0.02) and ALT (P= 0.03) along
with a lower BMI and a higher proportion of female gender
(Table 4). However, the sCD26 did not significantly correlate with
either ALT (rs = 0.155, P= 0.06, n = 153) or HCV RNA
(rs = 0.120, P= 0.14, n = 153), but correlated weakly albeit
significantly with IP-10 (rs = 0.261, P= 0.001, n = 150).
In order to further evaluate the predictive value of the baseline
sCD26 concentration and the 600 ng/mL sCD26 concentration
cut-off for treatment outcome, sCD26 concentrations in 36
patients chronically infected with HCV genotype 1 from an
independent study (the TTG1 trial) were assessed. In line with the
results from the DITTO-HCV study, patients achieving SVR
(n = 25) showed significantly lower sCD26 concentrations com-
pared with patients who did not achieve SVR (n = 11) (P= 0.02;
Figure 1C), however without any significant differences in DPPIV
activity (P= 0.4). The 600 ng/mL sCD26 cut-off value yielded a
93% (12 of 13) SVR rate for the patients below 600 ng/mL
compared with a 57% (13 of 23) SVR rate for of the patients above
600 ng/mL sCD26 (P= 0.03).
Table 6. Predictive values for SVR among the DITTO-HCV genotype 1 patients included in the study.
Parameter Sensitivity Specificity PPV NPV
CCrs12979860 32% (n = 81) 81% (n = 72) 65% (n = 40) 51% (n = 113)
AArs12980275 38% (n = 81) 78% (n = 72) 66% (n = 47) 53% (n = 106)
TTrs8099917 58% (n = 81) 47% (n = 72) 55% (n = 85) 50% (n = 68)
,150 pg/mL IP-10 33% (n = 81) 79% (n = 72) 64% (n = 42) 57% (n = 111)
,600 pg/mL IP-10 94% (n = 81) 24% (n = 72) 58% (n = 131) 77% (n = 22)
,600 ng/mL sCD26 65% (n = 81) 61% (n = 72) 65% (n = 81) 61% (n = 72)
Gender (Female) 25% (n = 81) 63% (n = 72) 43% (n = 47) 45% (n = 106)
,26106 IU/mL HCV RNA 63% (n = 81) 54% (n = 72) 61% (n = 84) 57% (n = 69)
,25 kg/m2 BMI 38% (n = 81) 38% (n = 72) 41% (n = 76) 35% (n = 77)
,43 years Age 58% (n = 81) 57% (n = 72) 60% (n = 78) 55% (n = 75)
Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for each parameter.
doi:10.1371/journal.pone.0056991.t006
Table 7. The impact of IL28B polymorphisms, baseline
plasma IP-10 and sCD26 concentrations on the likelihood of
achieving SVR for the DITTO-HCV genotype 1 patients
grouped using the IL28B genotypes, or the IP-10 or the sCD26
cut-offs.
NCBI dbSNP ID sCD26 ,600 ng/mL sCD26 .600 ng/mL P
rs12979860
CC 18/23 (78%) 8/17 (53%) 0.01
CT/TT 35/58 (60%) 20/55 (37%) 0.04
P 0.1 0.4
rs12980275
AA 21/28 (75%) 10/19 (53%) 0.1
AG/GG 32/53 (60%) 18/53 (34%) 0.01
P 0.2 0.2
rs8099917
TT 29/45 (64%) 18/40 (45%) 0.08
TG/GG 24/36 (67%) 10/32 (31%) 0.007
P 0.8 0.2
IP-10
,150 pg/mL 18/26 (69%) 9/16 (56%) 0.4
150–600 pg/mL 32/45 (71%) 17/44 (39%) 0.002
.600 pg/mL 3/10 (30%) 2/12 (17%) 0.5
P 0.04 0.1
P-values using x2 test.
doi:10.1371/journal.pone.0056991.t007
Figure 4. IFN-c+ CD8+ T cells after stimulation with genotype 1a
HCV specific HLA-A2 or HLA-A3 restricted peptides after in
vitro expansion. (A) Frequency of HCV-tetramer+ CD8+ T cells after
10 days in vitro expansion for patients (n = 28) grouped above or below
the median for sCD26. (B) Frequency of IFN-c+ CD8+ T cells after
10 days in vitro expansion for patients (n = 28) grouped above or below
the median for sCD26. Statistic using two-tailed Mann-Whitney U-test.
doi:10.1371/journal.pone.0056991.g004
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Interestingly, genotype 2 or 3 infected patients showed
significantly lower baseline sCD26 concentrations compared with
the genotype 1 patients (P= 0.03; Figure 3) with a trend towards
higher sCD26 concentrations for the three genotype 2/3 patients
not achieving SVR (median 498 vs. 618 ng/mL sCD26 for SVR
and non-SVR patients respectively; n = 58, P= 0.07). In addition,
grouping the patients above or below the 600 ng/mL sCD26 cut-
off resulted in 100% (37 of 37) SVR for the patients with
,600 ng/mL sCD26 and 86% (18 of 21) SVR for the .600 ng/
mL sCD26 patients (P= 0.02).
sCD26 Independently Predicts SVR
In order to determine if sCD26 independently impacts
treatment outcome for HCV genotype 1 infected patients, a
stepwise binary logistic regression was performed using the
baseline factors in Table 4. Lower sCD26 concentrations
independently predicted SVR among HCV genotype 1 infected
patients, with a 0.2% odds reduction for achieving SVR for each
incremental ng/mL sCD26 concentration increase (P , 0.05;
Table 5). The other independent baseline predictive markers of
SVR were lower HCV RNA concentration (P= 0.001), lower BMI
(P= 0.01), male gender (P= 0.004), and favorable IL28Brs12980275
genetic variant (P= 0.03). Furthermore, using the 600 ng/mL
sCD26 cut-off concentration resulted in 65% sensitivity, 61%
specificity, a 65% positive predictive value (PPV), and a 61%
negative predictive value (NPV) (Table 6).
We have previously reported that IP-10 levels are weakly but
significantly associated with IL28B genetic variants [13]. However,
no such association was observed between the baseline sCD26
concentration and IL28B rs12970860 (P= 0.4, Kruskal-Wallis test),
rs12980275 (P= 0.6), or rs809917 (P= 0.6) SNPs or IL28B
genotype distribution (Table 4) for the DITTO-HCV genotype
1 patients. In agreement with the observation that there was no
association between the baseline sCD26 concentration and IL28B
genotypes, having below the 600 ng/mL sCD26 cut-off value
significantly improved the treatment response rate in the genotype
1 DITTO-HCV patients with one or two IL28B risk alleles (CT/
TTrs12970860 P= 0.04, AG/GGrs12980275 P= 0.01, and rs809917
P= 0.007; Table 7). Similarly, lower sCD26 concentrations
significantly increased the likelihood of achieving SVR in patients
with baseline plasma IP-10 concentrations between 150 pg/mL
and 600 pg/mL (P= 0.002, Table 7).
Short-term HCV-specific CD8+ T cells
To evaluate the association between sCD26 concentrations and
the HCV-specific CD8+ T cell response, PBMCs collected prior to
therapy from 28 HLA-A2 or HLA-A3 positive patients were
analyzed for their ability to recognize and produce IFN-c after
stimulation with HLA-A2 or HLA-A3 restricted genotype 1a
peptides. When grouping the patients above or below 600 ng/mL
sCD26, it was observed that patients below the cut-off had
significantly more HCV-tetramer+ CD8+ T cells (P= 0.02,
Figure 4A) with a similar trend towards more IFN-c producing
CD8+ T cells following stimulation with HCV specific peptides
(P= 0.09, Figure 4B) compared with patients with sCD26 above
the cut-off concentration prior to therapy. In line with this
observation, a negative correlation between the sCD26 level and
the percent HCV-tetramer+ CD8+ T cells was observed
(rs =20.41, P= 0.03, n = 28). Furthermore, a strong correlation
was observed between the percentage of HCV-tetramer+ CD8+ T
cells and the percentage of IFN-c producing CD8+ T cells among
patients below the sCD26 cut-off (rs = 0.87, P= 0.0001, n = 18).
However, no such correlation was observed among patients above
the sCD26 cut-off (rs =20.11, P= 0.8, n = 10).
Additionally, no associations were noted between the frequen-
cies of HCV-tetramer+ CD8+ T cells (P= 0.4) or IFN-c+ CD8+ T
cells (P= 0.7) when grouping the patients above or below the
baseline median IP-10 concentration, or between the frequencies
of HCV-tetramer+ CD8+ T cells (P= 0.2) or IFN-c+ CD8+ T cells
(P= 0.5) and the IL28Brs12979860 CC versus non-CC genotypes.
Discussion
The main finding in the present study was that genotype 1
infected patients achieving SVR after treatment with pegIFN-a/
ribavirin demonstrated lower baseline plasma sCD26 concentra-
tions in two independent studies. Lower sCD26 concentrations
were not associated with IL28B genetic variation, and conse-
quently having lower baseline sCD26 concentrations significantly
improved the likelihood of achieving SVR among all IL28B SNP
risk alleles in HCV genotype 1 infected patients.
Additionally in these two studies, the sCD26 concentration was
a more reliable predictor of treatment outcome than DPPIV
activity. The surprisingly weak, but highly significant, correlation
between sCD26 concentration and DPPIV activity could in part
be explained by the existence of both cleaved membrane bound
and soluble CD26 in plasma with inherently different DPPIV
activity [37], or by differential impact of storage time or possible
freeze-thawing. It would have been of interest to measure the
impact of IP-10 truncation on SVR in the current studies, however
the levels of truncated IP-10 could not be quantified subsequent to
the lack of DPPIV inhibitors at the time of sampling, which is
necessary to prevent artifactual extravascular IP-10 truncation
[20]. Also, having female gender is usually a positive predictor of
SVR following HCV therapy, however, the complete DITTO
study has previously shown a higher SVR rate among male
patients [14] and accordingly the DITTO cohort in the present
study also demonstrated male gender to be associated with
favorable outcome (Table 5). CD26 has previously been suggested
to be a marker for liver disease [38] and higher sCD26 could thus
be an indicator of liver injury. In the present study however, the
distribution of fibrosis stages were not significantly different when
grouping the patients above or below the sCD26 cut-off (Table 4).
Also the sCD26 concentration did not significantly correlate with
ALT, and the genotype 2/3 cohort showed higher ALT despite
having lower sCD26 concentrations as compared with genotype 1
infected patients (Table 1 and 2).
Interestingly, it was observed that the sCD26 concentrations
were significantly lower among HCV genotype 2 and 3 infected
patients than among those infected with genotype 1. A similar
non-significant trend towards lower baseline IP-10 levels for HCV
genotype 2/3 in comparison with genotype 1/4 infected patients
has previously been reported from the same study cohort [14,15].
The mechanisms underlying these observations merit further
investigation.
Previous studies have correlated exhausted HCV-specific CD8+
T cells with treatment failure [26]. To evaluate whether the
sCD26 concentration could function as a marker of functional
HCV-specific T cells, short-term HCV-specific CD8+ T cells from
HLA-A2+ or HLA-A3+ patients were generated along with
assessment of the ability of these cells to produce IFN-c after
stimulation with HCV specific peptides. Interestingly, these data
suggested, albeit obtained from a small number of patients
(n = 28), that a low baseline sCD26 concentration may be
associated with the presence of functional HCV-specific T cells,
whereas higher sCD26 concentration could indicate a T cell
exhausted phenotype that has previously been described in
patients with chronic HCV infection who fail therapy [39]. The
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limited number of patients available for T cell analyzes only
differed significantly compared with the complete cohort with
regards to baseline IP-10 for the four genotype 2/3 infected
patients (Table 1 and 2), thus suggesting the evaluated patients
may be representative of the larger cohort. Treatment response
mechanisms, however, are complex, and the presence of
functional HCV-specific T cells does not consistently entail
improved likelihood of achieving SVR [28].
In conclusion and in agreement with the report by Casrouge et
al. (2011) [20], the present study suggests that lower baseline
sCD26 concentrations are associated with improved response to
combination therapy for HCV genotype 1 infection. Furthermore,
we could show that having sCD26 concentrations below the
600 ng/mL sCD26 cut-off value augmented the predictive value
of both baseline IP-10 concentration and IL28B genetic variants.
The very rapid clearance of HCV viremia observed following the
recent introduction of new DAAs for HCV, including nucleotide
polymerase inhibitors, likely will hamper the utility of on-
treatment levels of HCV RNA in tailoring therapy. Thus it is
reasonable to assume that baseline markers of response, such as
sCD26 concentration, may increase in importance in order to
personalize HCV treatment duration or choice of therapy as well
as reduce cost. However, further prospective studies to validate the
sCD26 concentration and its association with HCV-specific T cells
are warranted.
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